IL6 and diabetic kidney disease: This demonstrated that, in relatively advanced DKD due to type 2 DM, intravenous injection of allogeneic bone marrow-derived Stro3+ mesenchymal precursor cells was safe up to 24 weeks post-administration and was associated with preliminary evidence of efficacy including decreased serum IL-6 compared to placebo [62].